Evaluation of a quadrivalent inactivated vaccine for the protection of cattle against diseases due to common viral infections.
Efficacy of an inactivated quadrivalent vaccine containing infectious bovine rhinotracheitis (IBR) virus, parainfluenza type 3 (PI3) virus, bovine virus diarrhoea virus (BVDV) and bovine respiratory syncytial virus (BRSV) was assessed in naive bovine calves to evaluate short-term (4-18 weeks) and long-term (24-38 weeks) protection following the basic intramuscular vaccination regime of 2 inoculations a month apart. Vaccination was staggered between the long-term and the short-term groups by about 5 months so that both groups, along with a matched group of 6 unvaccinated (control) calves, could be challenged at the same time. Sequential challenges at intervals of 3-8 weeks were done in the order: IBR virus (intranasally, IN), PI3 virus (IN and intratracheally, IT), pestiviruses (IN) and BRSV (IN and IT). The IBR virus challenge produced febrile rhinotracheitis (FRT) in control calves but both the severity and the duration of FRT was significantly reduced in both vaccinated groups. The amount and the duration of IBR virus shed by the vaccinated groups was significantly reduced compared to the control group. Although PI3 virus, pooled pestivirus and BRSV challenges did not result in a noteworthy disease, challenge virus shedding (amount and duration) from the upper (all 3 viruses) and the lower (BRSV) respiratory tracts was significantly reduced in vaccinated groups. After pestivirus challenge, sera and leukocytes from all control calves were infectious for 6-9 days whereas virus was recovered only from leukocytes in vaccinated calves and only for 1.6-2.7 days. Thus a standard course of the quadrivalent vaccine afforded a significant protection against IBR virus, PI3 virus, BVDV and BRSV for at least 6 months.
Patel
J R
JR
Intervet UK Ltd, The Elms, Thicket Road, Houghton, Huntingdon, Cambridgeshire, PE28 2BQ, UK. jay.patel@intervet.com
D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000517:prevention & control* / Q000821:virology; D001908:Diarrhea Viruses, Bovine Viral / Q000276:immunology; D007242:Herpesvirus 1, Bovine / Q000276:immunology; D010224:Parainfluenza Virus 3, Human / Q000276:immunology; D022261:Respiratory Syncytial Virus Vaccines; D018112:Respiratory Syncytial Virus, Bovine / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome; D014611:Vaccination / Q000662:veterinary*; D017778:Vaccines, Combined; D015164:Vaccines, Inactivated; D014765:Viral Vaccines / Q000592:standards*; D014777:Virus Diseases / Q000517:prevention & control / Q000662:veterinary*; D017201:Virus Shedding
D022261:Respiratory Syncytial Virus Vaccines; D017778:Vaccines, Combined; D015164:Vaccines, Inactivated; D014765:Viral Vaccines